Compound
Target
Indication (Combination)
Stage of Development
Partner
Clinical Programs
AEG35156
X-Linked Inhibitor of Apoptosis (XIAP)
HCC (Sorafenib)
Randomized Phase 2
CLL/B-Cell Lymphoma
Phase I/2
AEG40826 (HGS1029)
Inhibitor of Apoptosis Proteins (IAPs)
Solid Tumors
Lymphoid Tumors
Phase I
Phase I
Preclinical Programs
AEGXXXXX
Inhibitor of Apoptosis Proteins (IAPs)
Inflammatory/Autoimmune Diseases
Preclinical Development Candidate Selection
About Aegera
|
Pipeline
|
Clinical Trials
|
Partnerships
|
Media
|
Careers
|
Contact Us
|
Français
© 2010 Aegera Therapeutics Inc. All rights reserved. Developed by
Grafika Designs
.
